Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Study Start Date
February, 2021
Scientific Title
A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Summary
This is a phase Ib/II open label study. The escalation part will characterize the safety and
tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments
(TNO155 and spartalizumab) in advanced solid tumor patients. After the determination of the
maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will
assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each
regimen at the maximum tolerated dose / recommended dose.
- Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors - Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations
- Tumors harboring driver mutations that have approved therapies or tumors with known activating KRAS, NRAS, HRAS, BRAF or PTPN11 (SHP2) mutations, with exception of KRAS G12C mutations - Active brain metastases - Clinically significant cardiac disease or risk factors at screening
Study Design
Primary purpose:
Treatment
,
Allocation:
Non-Randomized
,
Intervention model:
Sequential Assignment
,
Masking:
None (Open Label),
Conditions
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
Other Study ID Numbers
CJDQ443A12101
Locations
Please
to see your matching score and connect to trial sponsor